Our bold vision is shared by a group of global investors and professionals with years of experience in bringing new medical devices to market.
After initial funding from Sambatech Angel Investors, we raised $24M in Series A funding to advance our robotic platform for open surgery. The syndicate was led by Andera Partners with Panakès Partners, Fountain Healthcare and returning seed investor, Sambatech.
In 2022, we raised $75M in Series B funding to accelerate clinical trials and global commercialization. The round was led by Deerfield Management and RA Capital, with additional funding by existing investors and BioStar Capital. A Series B extension raised an additional $12M led by Wellington Partners and included BioStar Capital as an existing investor.
Backed by Leading-Edge Partners
The Symani Surgical System is a CE marked (CE 0051) medical device and is not approved or cleared by the FDA for commercial use in the U.S.
© 2023 Medical Microinstruments, Inc. All Rights Reserved.